| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Microbiology and Immunology [M. L. B., G. B. L., C. L. H., G. L. W.] and Urology [P. F. S., G. L. W.], Eastern Virginia Medical School, Norfolk, Virginia 23501
A monoclonal antibody (MAb) designated PD41 (IgG1k) was generated by hyperimmunizing BALB/c mice with a membrane preparation prepared from a moderately to poorly differentiated prostate carcinoma surgical specimen. The immunohistochemical reactivity of MAb PD41 was shown to be highly restricted to the ductal epithelia and secretions of prostate adenocarcinoma tissues. Sixty-five % of the prostate tumor specimens were stained with MAb PD41, whereas no staining of the fetal or benign prostate specimens was observed. PD41 reacted minimally with normal prostate tissues, with less than 1% of the epithelial cells staining. This MAb did not react with nonprostate carcinomas or to a variety of normal human tissues. Using both radioimmunoassay and immunofluorescent procedures, several cultured human tumor cell lines, human blood cells, and purified antigens to prostate-specific antigen and prostatic acid phosphatase also were found not to express the PD41 antigen. MAb PD41 also was shown to bind to the target antigen present in seminal plasma obtained from prostate carcinoma patients but not to seminal plasma from normal donors. Immunoblots of gel-separated components of prostate carcinoma tissue extracts indicate that the molecular weight of the proteins carrying the PD41 antigenic determinant can differ among individual tumors, ranging from Mr 90,000 to >400,000. However, in seminal plasma from prostate cancer patients, the predominant component recognized by PD41 is the diffuse Mr >400,000 band. It appears that this monoclonal antibody may recognize a prostate carcinoma-associated mucin-like antigen, which is preferentially expressed on prostate carcinomas, and therefore, may be a useful marker to distinguish benign prostate hyperplasia from prostate carcinoma.
1 This investigation was supported by NIH Grant CA26659.
2 To whom requests for reprints should be addressed at Department of Microbiology and Immunology, Eastern Virginia Medical School, 700 Olney Road, Norfolk, VA 23507.
Received 7/12/90. Accepted 11/29/90.
This article has been cited by other articles:
|
|
 |
|
  R. Foley, D. Hollywood, and M. Lawler Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease Endocr. Relat. Cancer, September 1, 2004; 11(3): 477 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Warren, L. Li, W. Song, E. Holle, Y. Wei, T. Wagner, and X. Yu In Vitro Targeted Killing of Prostate Tumor Cells by a Synthetic Amoebapore Helix 3 Peptide Modified with Two {gamma}-linked Glutamate Residues at the COOH Terminus Cancer Res., September 1, 2001; 61(18): 6783 - 6787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Papetti and I. M. Herman Controlling Tumor-Derived and Vascular Endothelial Cell Growth : Role of the 4F2 Cell Surface Antigen Am. J. Pathol., July 1, 2001; 159(1): 165 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Xu, J. A. Stolk, X. Zhang, S. J. Silva, R. L. Houghton, M. Matsumura, T. S. Vedvick, K. B. Leslie, R. Badaro, and S. G. Reed Identification of Differentially Expressed Genes in Human Prostate Cancer Using Subtraction and Microarray Cancer Res., March 1, 2000; 60(6): 1677 - 1682. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Bergeron, S. Champetier, Hélèn. LaRue, and Y. Fradet MAUB Is a New Mucin Antigen Associated with Bladder Cancer J. Biol. Chem., March 22, 1996; 271(12): 6933 - 6940. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
